Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quanterix, a developer of diagnostic tests based on Single Molecule Array (SiMoA) technology, has signed an evaluation agreement with Novartis Diagnostics.
Subscribe to our email newsletter
Quanterix CEO David Okrongly said they are excited to initiate this technology evaluation with Novartis, one of the world’s leading healthcare companies.
"Through this collaborative project, we hope to leverage the 1000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes," Okrongly added.